tetano
Editor, Senior Moderator
Clin Chem Lab Med
. 2021 Apr 9.
doi: 10.1515/cclm-2021-0214. Online ahead of print.
Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers
Christian Irsara[SUP] 1 [/SUP], Alexander E Egger[SUP] 1 [/SUP], Wolfgang Prokop[SUP] 1 [/SUP], Manfred Nairz[SUP] 2 [/SUP], Lorin Loacker[SUP] 1 [/SUP], Sabina Sahanic[SUP] 2 [/SUP], Alex Pizzini[SUP] 2 [/SUP], Thomas Sonnweber[SUP] 2 [/SUP], Barbara Holzer[SUP] 3 [/SUP], Wolfgang Mayer[SUP] 4 [/SUP], Harald Schennach[SUP] 4 [/SUP], Judith Loeffler-Ragg[SUP] 2 [/SUP], Rosa Bellmann-Weiler[SUP] 2 [/SUP], Boris Hartmann[SUP] 3 [/SUP], Ivan Tancevski[SUP] 2 [/SUP], G?nter Weiss[SUP] 2 [/SUP], Christoph J Binder[SUP] 5 [/SUP], Markus Anliker[SUP] 1 [/SUP], Andrea Griesmacher[SUP] 1 [/SUP], Gregor Hoermann[SUP] 1 6 [/SUP]
Affiliations
Abstract
Objectives: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections cause coronavirus disease 2019 (COVID-19) and induce a specific antibody response. Serological assays detecting IgG against the receptor binding domain (RBD) of the spike (S) protein are useful to monitor the immune response after infection or vaccination. The objective of our study was to evaluate the clinical performance of the Siemens SARS-CoV-2 IgG (sCOVG) assay.
Methods: Sensitivity and specificity of the Siemens sCOVG test were evaluated on 178 patients with SARS-CoV-2-infection and 160 pre-pandemic samples in comparison with its predecessor test COV2G. Furthermore, correlation with virus neutralization titers was investigated on 134 samples of convalescent COVID-19 patients.
Results: Specificity of the sCOVG test was 99.4% and sensitivity was 90.5% (COV2G assay 78.7%; p<0.0001). S1-RBD antibody levels showed a good correlation with virus neutralization titers (r=0.843; p<0.0001) and an overall qualitative agreement of 98.5%. Finally, median S1-RBD IgG levels increase with age and were significantly higher in hospitalized COVID-19 patients (median levels general ward: 25.7 U/mL; intensive care: 59.5 U/mL) than in outpatients (3.8 U/mL; p<0.0001).
Conclusions: Performance characteristics of the sCOVG assay have been improved compared to the predecessor test COV2G. Quantitative SARS-CoV-2 S1-RBD IgG levels could be used as a surrogate for virus neutralization capacity. Further harmonization of antibody quantification might assist to monitor the humoral immune response after COVID-19 disease or vaccination.
Keywords: COVID-19; SARS-CoV-2; neutralization assay; sensitivity; serology; specificity.
. 2021 Apr 9.
doi: 10.1515/cclm-2021-0214. Online ahead of print.
Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers
Christian Irsara[SUP] 1 [/SUP], Alexander E Egger[SUP] 1 [/SUP], Wolfgang Prokop[SUP] 1 [/SUP], Manfred Nairz[SUP] 2 [/SUP], Lorin Loacker[SUP] 1 [/SUP], Sabina Sahanic[SUP] 2 [/SUP], Alex Pizzini[SUP] 2 [/SUP], Thomas Sonnweber[SUP] 2 [/SUP], Barbara Holzer[SUP] 3 [/SUP], Wolfgang Mayer[SUP] 4 [/SUP], Harald Schennach[SUP] 4 [/SUP], Judith Loeffler-Ragg[SUP] 2 [/SUP], Rosa Bellmann-Weiler[SUP] 2 [/SUP], Boris Hartmann[SUP] 3 [/SUP], Ivan Tancevski[SUP] 2 [/SUP], G?nter Weiss[SUP] 2 [/SUP], Christoph J Binder[SUP] 5 [/SUP], Markus Anliker[SUP] 1 [/SUP], Andrea Griesmacher[SUP] 1 [/SUP], Gregor Hoermann[SUP] 1 6 [/SUP]
Affiliations
- PMID: 33837679
- DOI: 10.1515/cclm-2021-0214
Abstract
Objectives: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections cause coronavirus disease 2019 (COVID-19) and induce a specific antibody response. Serological assays detecting IgG against the receptor binding domain (RBD) of the spike (S) protein are useful to monitor the immune response after infection or vaccination. The objective of our study was to evaluate the clinical performance of the Siemens SARS-CoV-2 IgG (sCOVG) assay.
Methods: Sensitivity and specificity of the Siemens sCOVG test were evaluated on 178 patients with SARS-CoV-2-infection and 160 pre-pandemic samples in comparison with its predecessor test COV2G. Furthermore, correlation with virus neutralization titers was investigated on 134 samples of convalescent COVID-19 patients.
Results: Specificity of the sCOVG test was 99.4% and sensitivity was 90.5% (COV2G assay 78.7%; p<0.0001). S1-RBD antibody levels showed a good correlation with virus neutralization titers (r=0.843; p<0.0001) and an overall qualitative agreement of 98.5%. Finally, median S1-RBD IgG levels increase with age and were significantly higher in hospitalized COVID-19 patients (median levels general ward: 25.7 U/mL; intensive care: 59.5 U/mL) than in outpatients (3.8 U/mL; p<0.0001).
Conclusions: Performance characteristics of the sCOVG assay have been improved compared to the predecessor test COV2G. Quantitative SARS-CoV-2 S1-RBD IgG levels could be used as a surrogate for virus neutralization capacity. Further harmonization of antibody quantification might assist to monitor the humoral immune response after COVID-19 disease or vaccination.
Keywords: COVID-19; SARS-CoV-2; neutralization assay; sensitivity; serology; specificity.